Dara Calleary (Mayo, Fianna Fail) | Oireachtas source

The Minister has teed it up for me. The company involved in the merger is sniffing around - for want of a better phrase - other Irish companies. I welcome the statement that there are no large-scale redundancies on the Minister's radar. Does IDA Ireland have a strategy in place, not just for the specific company mentioned but also for the pharmaceutical sector generally? Many companies involved in the sector are, effectively, asset-stripping, while floating around and looking for potentially good research and development opportunities that may result in a commercial return for their own investment companies. Is the Department aware of this and, if so, is it working on a strategy for the pharmaceutical sector to guide it through this phase?

See this speech in context